2 results
Approved WMOPending
Primary Objective • To determine whether ITCA 650 is non-inferior either to empagliflozin or to glimepiride in reducing glycosylated hemoglobin A1c (HbA1c) or weight in patients with T2D following 65 weeks of treatment. The non-inferiority margins…
Approved WMOWill not start
To assess the pharmacokinetics and safety of naloxegol in paediatric patients ages > 6 months to < 18 years receiving treatment with opioids.